Cidara Therapeutics, Inc. (CDTX)
NASDAQ: CDTX · Real-Time Price · USD
15.12
-0.51 (-3.26%)
Nov 20, 2024, 4:00 PM EST - Market closed
Cidara Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Cidara Therapeutics stock have an average target of 30.5, with a low estimate of 24 and a high estimate of 40. The average target predicts an increase of 101.72% from the current stock price of 15.12.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for CDTX stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 4 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 4 | 4 | 4 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $24 | Strong Buy | Reiterates | $24 | +58.73% | Nov 11, 2024 |
| Guggenheim | Guggenheim | Strong Buy Initiates $33 | Strong Buy | Initiates | $33 | +118.25% | Nov 8, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $24 | Strong Buy | Reiterates | $24 | +58.73% | Oct 22, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $24 | Strong Buy | Reiterates | $24 | +58.73% | Sep 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $24 | Hold → Strong Buy | Upgrades | $24 | +58.73% | Aug 14, 2024 |
Financial Forecast
Revenue This Year
10.20M
from 63.91M
Decreased by -84.04%
Revenue Next Year
n/a
from 10.20M
EPS This Year
-26.51
from -5.25
EPS Next Year
-10.16
from -26.51
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 11.8M | n/a | n/a | ||
| Avg | 10.2M | n/a | n/a | ||
| Low | 8.6M | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -81.6% | - | - | ||
| Avg | -84.0% | - | - | ||
| Low | -86.5% | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -24.68 | -7.04 | -5.43 | ||
| Avg | -26.51 | -10.16 | -9.67 | ||
| Low | -30.06 | -12.11 | -15.27 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.